Literature DB >> 949032

Phentolamine.

L Gould, C V Reddy.   

Abstract

The clinical uses of phentolamine have widened since its introduction as an anti-hypertensive agent. The vasodilating action of the drug as well as its postive inotropic effects have led to its use in treating congestive heart failure. Recently, phentolamine has been use by several groups to improve left ventricular function in acute myocardial infarction. There appears to be great promise for the use of phentolamine in this clinical setting. The drug given intravenously or orally can suppress ventricular premature beats and supraventricular premature beats. However, the experience of phentolamine as an antiarrhythmic agent is still limited. Similarly, the relief of angina pectoris by phentolamine requires confirmation by additional clinical studies. Phentolamine can be used as a provocative test in idiopathic hypertrophic subaortic stenosis. Since it does not produce cardiac arrhythmias, it may be safer than isoproterenol. The comparative effectiveness of phentolamine and isoproterenol in diagnosing I.H.S.S. is unknown. Phentolamine has been advocated for several years as a beneficial agent for the treatment of shock. The experience is still limited to a few groups who have reported favorable results. Phentolamine has been used as a bronchodilator and a pulmonary artery dilator. The preliminary reports appear favorable. However, continused investigation is warranted. A sensitive measurement of the blood levels of phentolamine is not available. When this is accomplished, further insight into the metabolism of this drug will be forthcoming.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 949032     DOI: 10.1016/s0002-8703(76)80121-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Effects of alpha-adrenoceptor and of combined sympathetic and parasympathetic blockade on cardiac performance and vascular resistance.

Authors:  H Kelbaek; H Frandsen; J Hilsted; N J Christensen; S L Nielsen
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

2.  Phentolamine block of KATP channels is mediated by Kir6.2.

Authors:  P Proks; F M Ashcroft
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Importance of cardiac and vascular beta-receptors in the action of phentolamine.

Authors:  A Hoffmann; M Meier
Journal:  Agents Actions       Date:  1977-09

4.  [Acute combined alpha- and beta-adrenergic blockade in essential hypertension: effects on blood pressure, renal function, renin, and aldosterone].

Authors:  U Grüninger; R Akert; H Hunkeler; E Wegmüller; P Weidmann; J Hodler
Journal:  Klin Wochenschr       Date:  1979-07-15

5.  Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure.

Authors:  S K Mujais; F M Fouad; S C Textor; R C Tarazi; E L Bravo; N Hart; R W Gifford
Journal:  Br Heart J       Date:  1984-07

6.  A comparison of the electrophysiological actions of phentolamine with those of some other antiarrhythmic drugs on tissues isolated from the rat heart.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

7.  Comparison of the cardiovascular effects of phentolamine, sodium nitroprusside and nitroglycerin in anaesthetized cats (comparison of vasodilators).

Authors:  A Hoffmann; M Meier
Journal:  Basic Res Cardiol       Date:  1977 Jul-Aug       Impact factor: 17.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.